First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors

BACKGROUND: NEO201 is a humanized IgG1 monoclonal antibody (mAb) generated against tumor-associated antigens from patients with colorectal cancer. NEO-201 binds to core 1 or extended core 1 O-glycans expressed by its target cells. Here, we present outcomes from a phase I trial of NEO-201 in patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Cole, Christopher B., Morelli, Maria Pia, Fantini, Massimo, Miettinen, Markku, Fetsch, Patricia, Peer, Cody, Figg, William D., Yin, Tyler, Houston, Nicole, McCoy, Ann, Lipkowitz, Stanley, Zimmer, Alexandra, Lee, Jung-min, Pavelova, Miroslava, Villanueva, Erin N., Trewhitt, Kathryn, Solarz, B. Brooke, Fergusson, Maria, Mavroukakis, Sharon A., Zaki, Anjum, Tsang, Kwong Y., Arlen, Philip M., Annunziata, Christina M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10053355/
https://www.ncbi.nlm.nih.gov/pubmed/36991390
http://dx.doi.org/10.1186/s13046-023-02649-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10053355/
https://www.ncbi.nlm.nih.gov/pubmed/36991390
http://dx.doi.org/10.1186/s13046-023-02649-6

Ejemplares similares